What Dymind does

Dymind (深圳市帝迈生物技术有限公司) is a privately held Chinese in vitro diagnostics (IVD) medical device company founded in 2013 and headquartered in Shenzhen. The company develops, manufactures and sells hematology analyzers and adjacent IVD platforms — coagulation analysis, point-of-care testing (POCT), and immunodiagnostics — anchored by its pioneering integrated co-testing machines and supported by a reagent and consumables (耗材) ecosystem that produces recurring revenue from the installed base. Dymind publicly reports distribution across 140+ countries and regions, with overseas subsidiaries in Indonesia (2022), the United States via DYMUSA (2024), Italy, and Mexico, plus its first overseas assembly line for the DH-8000 platform in Turkey (2026). The company holds over 1,200 patents and multi-jurisdictional certifications including CE, ISO13485, ISO9001, KGMP, TÜV, SGS, and CNAS. Within China, Dymind ranks second among domestic brands in the blood-analysis market and reports international revenue above 40% of total, with management citing 105x revenue growth over a nine-year window.

The company's product portfolio has expanded from core blood-cell analysis into specialty IVD (DH-87CS[H] HbA1c for glycated hemoglobin, MF1260 allergy IgE) and into adjacent verticals via the Dymind Animal Medical Technology subsidiary and the NGID Smart Inspection Business Division. Under the AI Medical New Ecosystem strategy launched in 2026, Dymind is positioning AI disease-warning models (Mediterranean anemia, sepsis, tumor cells), AI fluorescence 3D analysis, and an AI-powered assembly line codifying 41 international-standard re-examination rules as a platform layer above the hardware business, with a smart-laboratory offering branded 帝惠检. More than 40% of staff are in R&D and R&D spend exceeds 20% of revenue, under CEO Zhai Liuwei (翟留伟) and CTO Huo Ziling (霍子凌), the latter associated with development of the world's first 5-part differential algorithm.

Dymind operates a hybrid go-to-market combining direct enterprise sales to hospital and laboratory customers with regional channel partners, and uses reference deployments (e.g., The First Affiliated Hospital of Zhengzhou University in China; Gaziantep Hospital in Turkey; Meikang Bio-Tech) to anchor new geographies. The revenue model follows the conventional IVD razor-and-blade logic — instrument placement drives multi-year reagent and consumable pull-through — supplemented by an emerging services vector through the NGID Smart Inspection division. The company has added an Operations Management Department led by the CTO, indicating a transition from R&D-led scaling toward operations-managed scaling as the installed base and overseas footprint mature.

Name

Dymind

Legal name

深圳市帝迈生物技术有限公司

Website

https://dymind.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Dymind is a Shenzhen-based privately held IVD medical device company developing hematology analyzers, coagulation, POCT, and immunodiagnostics with over 1,200 patents and distribution across 140+ countries, serving hospitals, primary-care centers, and veterinary end-segments.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostic Medical Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• Hematology analyzers
• In vitro diagnostics
• Coagulation analyzers
• POCT analyzers
• Immunoassay analyzers

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Hardware Sales: Sale of in vitro diagnostic instruments including blood cell analyzers, coagulation analyzers, POCT devices, immune analyzers, and animal health analyzers. Products sold directly to hospitals and through distribution partners.
2. IVD Reagents and Consumables: Recurring revenue from proprietary reagents, consumables, and calibration/control products that accompany instrument installations, providing a consumables revenue stream tied to installed base.
3. Professional Services and Support: Pre-sales consultation, after-sales service, academic training, and laboratory solutions consulting services provided alongside product sales.
4. Smart Laboratory Solutions: Dymind provides integrated laboratory solutions including the 帝惠检 (Dihuijian) medical laboratory standardized intelligent management platform covering document management, electronic records, review preparation, and ISO15189 accreditation support, generating software/service revenue.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels11 records

Core offering

Dymind designs, manufactures, and sells in vitro diagnostic (IVD) medical devices and proprietary reagents for clinical laboratories and point-of-care settings. Its portfolio spans blood cell analyzers (CBC, five-part differential, integrated co-testing machines combining CBC with CRP/SAA/HbA1c), coagulation analyzers, POCT multi-functional analyzers, immunoassay analyzers, and veterinary blood analyzers, complemented by a smart laboratory management software platform (帝惠检) and recurring reagent/consumable revenue tied to its installed instrument base.

Product overview

Dymind is an in vitro diagnostics (IVD) medical device company offering a diversified portfolio of blood analysis, coagulation, POCT, immunology, and animal health products. The portfolio is organized around several core product lines: (1) Blood Cell Analyzers — including five-part and three-part differential analyzers (DH series, UN series, D series), with leading co-detection instruments integrating CBC with CRP/SAA/HbA1c on a single platform (DM79X, DM75X, DH71CRP, DH76CRP, D6-CRP, UN73); (2) Automated Blood Analysis Assembly Lines — the 行云智检 (Cloud Walker) series (DH-6000, DH-8000) providing end-to-end automation from sample preprocessing through analysis, re-examination, and quality control; (3) Coagulation Analyzers — CA series (CA520, CA1200, CA1205) combining optical and magnetic bead methods; (4) POCT Multi-Functional Analyzers — DP-H series (DP-H50, DP-H20, DP-H10) for primary healthcare and point-of-care settings; (5) Immunoassay Analyzers — MF series (MF1280, MF1260) for allergy and autoimmune disease testing; (6) Animal Health — veterinary blood analyzers (DH31Vet, DF55Vet, DF50 Lab, DM60 Lab, DP-H50 Vet); (7) AI-Powered Solutions — disease early screening, smart laboratory management (帝惠检), and county-level medical solutions built on AI, IoT, and cloud platforms. The products are distributed globally to over 140 countries and regions.

Differentiator

Problem solved

Functional benefit

Brands

• 帝惠检: 帝惠检医学检验科标准化智慧化管理平台，通过文件电子化、标准化管理，实现快速检索、版本控制、权限管理及作废文件处理，检验知识库助力人员能力提升。
• NGID 智检事业部
• 帝迈享·行云智检
• 帝迈畅·敏测精检

Products and services

• DH-87CS[H] Automated Blood Immunoassay Glycohemoglobin Analyzer (DH-87CS[H] 全自动血液免疫糖化血红蛋白分析仪) An automated blood immunoassay glycohemoglobin (HbA1c) analyzer extending Dymind's immunoassay portfolio into diabetes monitoring, enabling glycosylated hemoglobin quantification alongside blood routine and infection marker testing for hospital laboratories managing chronic disease patients.
• DM75X Automated Blood Immunoassay Analyzer (DM75X 全自动血液免疫分析仪) An automated blood immunoassay analyzer that integrates five-part blood differential, CRP, and HbA1c testing in a single instrument, featuring an automated capillary blood sampling system, intelligent automated maintenance cleaning, and a dedicated low-value detection mode for hospital and clinical laboratory use.
• MF1260 Allergen IgE Multi-Panel Quantitative Detection Platform (MF1260 过敏原IgE多联定量检测平台) An allergy antigen IgE multi-panel quantitative detection platform designed for minimal blood sample testing, enabling multiple quantitative allergy tests from a single finger-prick blood sample in allergy and autoimmune disease detection.
• DH-2000T Automated Blood Immunoassay Analyzer (DH-2000T 全自动血液免疫分析仪) Automated blood immunoassay analyzer under the Sharing Cloud Smart Inspection (行云·行云智检) product line capable of single-tube CBC + CRP/SAA/PCT/IL-6 combined detection with automatic sample rejection and re-examination for abnormal samples without manual intervention. Designed for hospital laboratories performing combined hematology and infection-marker testing.
• DH-6000 Automated Blood Analysis Assembly Line (DH-6000 全自动血液分析流水线) Automated blood analysis assembly line featuring nucleic acid fluorescent staining 3D analysis technology for accurate six-part white blood cell classification, reticulocyte detection, and abnormal cell screening, with integrated DH-108T module for CRP, SAA, PCT/IL-6 quantitative detection. Targeted at mid-to-large hospital laboratories.
• DH-8000 Automated Blood Analysis Assembly Line (DH-8000 全自动血液分析流水线) Flagship automated blood analysis assembly line under the 行云2.0 series, integrating AI technology to analyze detection results, alarm information, and graphical data. Supports automatic re-examination with built-in 41 international standard re-examination rules, I/L/U-shaped flexible layouts, and integration with SPS sample preprocessing system for AI-powered full-chain inspection. Deployed at Gaziantep Hospital in Turkey processing 70,000 monthly samples.
• DH-800 Series Automated Blood Cell Analyzer (DH-800系列 全自动血液分析仪) Blood cell analyzer series within the 行云2.0 assembly line family, applying AI fluorescence 3D analysis technology, intelligent warm-bath RBC cold agglutination solutions, and PLT full-range interference resolution to ensure accuracy and reliability of routine blood tests in hospital and clinical laboratory settings.
• DH-80 Series Automated Blood Cell Analyzer (DH-80系列 全自动血液分析仪) Five-in-one multi-parameter detection blood cell analyzer series (including DH-88CS) using four-dimensional laser scattering technology for improved WBC accuracy, dye-free PLT-S detection for platelets, and RBC V/HC scatter plots to assist in distinguishing types of anemia for hospital laboratories.
• DM79X Automated Blood Immunoassay All-in-One Analyzer (DM79X 全自动血液免疫一体机) Flagship all-in-one blood immunoassay analyzer integrating five-part blood differential, CRP, and SAA ('new three routine tests') in a single instrument, delivering results in one minute. Features multi-angle laser scattering, flow cytometry, and cell chemistry staining; supports venous blood, capillary blood, and pre-diluted blood with automatic closed-sample inlet for hospital and clinical laboratory use.
• DH76CRP Five-Part Blood Cell Analyzer (DH76CRP 五分类血液细胞分析仪) Five-part blood cell analyzer with automated capillary blood sampling designed for emergency and outpatient settings. Requires only 20 μL of blood for on-machine testing and 80 μL for automated sampling, featuring intelligent mixing system for standardized batch testing of micro-blood samples.
• DH71CRP Five-Part + CRP Automated Blood Cell Analyzer (DH71CRP 五分类+CRP全自动血液细胞分析仪) Five-part blood cell analyzer with integrated CRP detection via dual-channel design. Supports automatic and manual (emergency) sampling with priority queuing for STAT samples, and automatic obstruction clearance without manual intervention.
• D6-CRP Five-Part Blood Cell Analyzer (D6-CRP 五分类血液细胞分析仪) Five-part blood cell analyzer with integrated CRP detection achieving combined testing in one minute. Supports venous, capillary, and pre-diluted blood modes using semiconductor laser scattering technology with 3 histograms and 4 scatter plots.

Quantifiable outcome

• One-minute results for CBC+CRP+SAA three-in-one test from a single blood tube, improving laboratory efficiency significantly
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• 美康生物科技股份有限公司 (Meikang Bio-Tech Co., Ltd.)coreStrategic or Co-development Partner · 13 October 2025Meikang Bio is a long-term strategic partner and investor of Dymind. Chairman Zou Bingde attended Dymind's 2025 National Strategic Partner Conference and participated in the joint launch of the Smart Laboratory Overall Solution. Meikang Bio's International Trade Deputy General Manager Li Haoxiang attended the global partner conference, emphasizing the strength of the strategic alliance.
• 白求恩精神研究会检验医学分会 (Bethune Spirit Research Association — Laboratory Medicine Branch)coreStrategic or Co-development Partner · 13 October 2025President Dong Shukui attended Dymind's 2025 National Partner Conference, witnessing the launch of the AI Medical Diagnosis New Ecosystem strategy. He highly praised Dymind's AI-reconstructed value strategy and 'technology depth + efficiency innovation + value co-creation' approach as a benchmark for the IVD industry transformation.
• 体外诊断网 (In Vitro Diagnosis Network)minorGTM or Marketing Partner · 13 October 2025IVD industry media platform founded by Li Guangyu, which co-launched the Disease Early Screening Solution with Dymind. Li Guangyu provided high evaluation of Dymind's AI technology as a differentiated advantage and the company's alignment with six core traits of excellent IVD enterprises.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Maccura Biotechnology Co., Ltd. Chinese IVD manufacturer with biochemistry, immunoassay, and hematology product lines. Direct competitor in domestic tenders and increasingly in international markets through distributor channels.
• Mindray Medical International: Largest Chinese IVD and medical device manufacturer with overlapping hematology, chemistry, and immunoassay analyzers. Direct competitor in domestic Chinese IVD market and increasingly in international emerging markets where both target cost-sensitive hospitals.
• Sysmex Corporation: Global leader in hematology and IVD with broad blood cell analyzer, coagulation, and urinalysis portfolio. Directly comparable to Dymind as the dominant incumbent in the same hematology category, with deeper reagent catalogs and longer reference lab track record.
• Boule Diagnostics AB: Sweden-based pure-play hematology instrument manufacturer serving human and veterinary markets. Highly comparable as a focused hematology player with similar product breadth across five-part differentials, veterinary analyzers, and reagents.
• Sinocare Inc. Chinese IVD company specializing in blood glucose monitoring and expanding into broader IVD including hematology and chemistry. Comparable Chinese peer competing in grassroots and consumer-adjacent diagnostic segments.
• Snibe (Shenzhen New Industries Biomedical): Chinese chemiluminescence immunoassay specialist with growing IVD portfolio. Comparable Shenzhen-based IVD company targeting similar hospital channels both domestically and internationally.
• HORIBA Medical: Hematology and clinical chemistry instrument manufacturer with global distribution. Directly comparable mid-sized specialist in the blood cell analysis space, similar to Dymind's positioning in tier-2 international hospital accounts.

Broad incumbents

• Roche Diagnostics: Global IVD leader with comprehensive hematology, immunoassay, and clinical chemistry portfolio. Broad incumbent competing in premium hospital accounts with integrated middleware and broad reagent menus.
• Beckman Coulter (Danaher): Global IVD incumbent under Danaher with strong hematology (Dxh series) and clinical chemistry positions. Competes head-to-head with Dymind's DH/DM-series analyzers in mid-to-high-tier international hospital tenders, with broader menu and longer reagent history.
• Abbott Diagnostics: Global IVD incumbent with hematology, immunoassay, and point-of-care offerings. Broad incumbent serving similar hospital segments with established reference lab relationships and global service network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/DymindBiotech
• Facebookfacebook.com/DymindBiotechofficial
• LinkedInlinkedin.com/company/dymindbiotech

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dymind